A Phase 1b, Open-Label Study to Evaluate the Safety of AMG 479 in Combination with Gemcitabine as First-line Therapy for Metastatic Pancreatic Cancer

Status

Unknown

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080221160

Enrollment

Registered

2010-07-21

Start date

2010-07-21

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced solid tumor

Interventions

investigational material(s) Generic name etc : AMG 479 INN of investigational material : Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Major inclusion criteria include the following: 1)Subjects must have histologically or cytologically documented and confirmed metastatic adenocarcinoma of the pancreas 2)Eastern Cooperative Oncology Group (ECOG) score of 0 or 1 3)Men or women over 20 years old of age

Exclusion criteria

Exclusion criteria: Major exclusion criteria include the following: 1)Islet cell, acinar cell carcinoma, non-adenocarcinoma, (eg, lymphoma, sarcoma, etc), adenocarcinoma originated from biliary tree or cystadenocarcinoma 2)Known history of central nervous system metastases 3)Internal or external biliary drain 4)A history of other malignancies

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026